PTO/SB/21 (09-04 Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE aduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Application Number 10/767,329 Filing Date RANSMITTAL 01/29/2004 First Named Inventor **FORM** Sean D. Monahan Art Unit 1615 **Examiner Name** David L. sed for all correspondence after initial filing) Attorney Docket Number Mirus.041.01 Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Fee Transmittal Form Drawing(s) Appeal Communication to Board Licensing-related Papers Fee Attached of Appeals and Interferences Appeal Communication to TC Petition Amendment/Reply (Appeal Notice, Brief, Reply Brief) Petition to Convert to a Proprietary Information After Final **Provisional Application** Power of Attorney, Revocation Status Letter Affidavits/declaration(s) Change of Correspondence Address Other Enclosure(s) (please Identify Terminal Disclaimer **Extension of Time Request** below): Request for Refund **Express Abandonment Request** CD, Number of CD(s)_ Information Disclosure Statement Landscape Table on CD Certified Copy of Priority Remarks Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name Mirus Bio Corporation Signature \mathscr{U} Printed name Kirk Ekena Reg. No. Date 56,672 12/28/2005 CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: Signature

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Kirk Ekena

Typed or printed name

Date

12/28/2005

| Application of: Sean D. Monahan, Vladimir G. Budker, Kirk Ekena, |) |
|---|---------------------------|
| Lisa Nader |) |
| Serial No.: 10/767,329 | Examiner: Varile, David L |
| Filed: 01/29/2004 |) |
| Group Art Unit: 1615 | ,) |

For: Protein and Peptide Delivery to Mammalian Cells In Vitro

INFORMATIONAL STATEMENT

Commissioner of Patents P.O. BOX 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. 1.56, applicant hereby calls to the attention of the Patent and Trademark Office the publications listed on the attached PTO 1449. This information statement supplements the previously filed information statement.

No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.





US patent

| Patent No. | ADEMOSTS. | Applicant | Issue date |
|--------------|-----------|-----------------|------------|
| US 5,858,398 | | Cho et al. | 01/12/1999 |
| US 5,516,703 | | Caldwell et al. | 05/14/1996 |
| US 4,589,538 | | Ribi et al. | 08/22/1999 |

Foreign patent publication

| Publication No. | Applicant | Publication date |
|-----------------|---------------------|------------------|
| EP 0 335 133 | Abbott Laboratories | 03/06/1989 |

REFERENCES CITED

Maa et al. "Biopharmaceutical powders: particle formation and formulation considerations." Curr. Pharm. Biotech. 2000 Vol. 1 p. 283-302

Applicant respectfully requests that these publications be expressly considered during the prosecution of this application and made of record herein and appear among the 'References Cited' on any patent to issue herefrom.

Respectfully submitted,

Kirk Ekena Reg. No. 56,672 Mirus Bio Corporation 505 S. Rosa Rd. Madison, WI 53719 (608) 441-2829 I hereby certify that this correspondence is being sent by United States Postal Service mail to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on:

Viole Elema

Kirk Eken

| TPE | PE | | | | Application Number | 10/676,329 |
|---------------------------|----------|-------|-------|---------|------------------------|-----------------|
| 1° INFORMATION DISCLOSURE | | | | OSURE | Filing Date | 01/29/2004 |
| NG E | TIEU | | | | First Named Inventor | Sean D. Monahan |
| HUL | TATE | MENIB | Y APP | LICANI | Art Unit | 1615 |
| MAREMARY | / | | | | Examiner Name | Vanik David L. |
| | Sheet | 1 | of | 1 | Attorney Docket Number | Mirus.041.01 |
| OIPE | | | | U.S. P. | ATENT DOCUMENTS | |

DEC 28 2005

| _ | 1 | | | | | |
|-------------|----------|------|--------------------|------------------|-----------------------------|-------------------------------|
| Ž | 3 | | Document Number | | | Pages, Columns, Lines, Where |
| 5 [| kaminer | Cite | | Publication Date | | Relevent Passages or Relevant |
| ′∟ | Initials | No. | Number – Kind Code | MM-DD-YYYY | Applicant of Cited Document | Figures Appear |
| d | 1 | | | | | |
| \$ } | , | | US-5,858,398 | 01/12/1999 | Cho et al. | |
| _ | | | US-5,516,703 | 05/14/1996 | Caldwell et al. | |
| | | | US-4,589,538 | 08/22/1999 | Ribi et al. | |

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

| Examiner Initials | Document Number | Publication Date | Country or Patent Office | Class | Sub Class | <u>Tra</u> yes | nsl. no |
|-------------------|-----------------|---------------------|--------------------------|-------|--------------|-------------------|------------|
| | EP 0335 133 | 03/06/1989 | Abbott Laboratories | | | | |

NON PATENT LITERATURE DOCUMENTS

| Examiner | Cite | | |
|----------|------|---|---|
| Initials | No. | | T |
| | | Maa et al. "Biopharmaceutical powders: particle formation and formulation | |
| İ | | considerations." Curr. Pharm. Biotech. 2000 Vol. 1 p. 283-302 | |

| Examiner | Date Considered | |
|-----------|--------------------|--|
| Signature | Collsidered | |